Speaker: Marc Emmenegger
Group Prof. Dr. Adriano Aguzzi
Institute of Neuropathology, University Hospital Zurich, University of Zurich
Greater availability of sequencing technologies has accelerated the trend towards personalized medicine, most evident in clinical oncology. However, genome sequencing of cancer patients reflects only a small fraction of the potential of personalized medicine. In contrast, using our methodology, we are able to investigate the immune repertoire of large numbers of unselected individuals. While monoclonal antibodies obtained from humans may be utilized for the development of powerful and highly specific therapeutics, another important aspect is the ability to identify hidden disease associations by correlating the medical record with the individual antibody reactivity profile. We expect our pioneering approach to sustainably advance precision medicine and thus markedly promote personalized health in Switzerland. Read the abstract...
All seminars are live-streamed, recorded and hosted on the DCC SWITCHTube channel. If you wish to be added to the distribution list, please complete the form on the Seminar and Training page.